The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Sat., Aug. 17, 4:32 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #24. Celgene Corporation Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders

Acquirer: Celgene Corporation (NASDAQ:CELG)
Acquiree: Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Details: Celgene Corporation (NASDAQ:CELG) entered into a global license agreement with Nogra Pharma Limited, a private pharmaceutical company based in Dublin, Ireland, to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease and other indications.

Celgene is a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Co.'s primary commercial stage products include: REVLIMID®, an oral immunomodulatory drug; POMALYST®/IMNOVID®, a proprietary, small molecule; OTEZLA®, an oral small-molecule inhibitor of phosphodiesterase 4 for cyclic adenosine monophosphate; ABRAXANE®, a solvent-free chemotherapy product; and VIDAZA®, a pyrimidine nucleoside analog. In addition, Co. provides other product sales and licensing arrangements.

Celgene SEC Filing Email Alerts Service

Open the CELG Page at The Online Investor »

Company Name: 
Celgene Corp
Stock buyback: 
CELG buyback
Drugs & Pharmaceuticals
Number of ETFs Holding CELG: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the CELG Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Hold (2.12 out of 4)
5th percentile
(ranked lower than approx. 95% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 24 of 100 Page |

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.